Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sympathetic activation is a hallmark of end-stage renal disease and adversely affects cardiovascular prognosis. Hypertension is present in the vast majority of these patients and plays a key role in the progressive deterioration of renal function and in the exceedingly high rate of cardiovascular events. Selective catheter-based renal denervation has been shown to be safe and effective in attaining improved and sustained blood pressure control in patients with resistant hypertension and normal renal function. The investigators hypothesize that catheter-based renal denervation is a safe and effective intervention to achieve sustained reduction in sympathetic nerve activity, BP and target organ damage in hypertensive End-Stage Renal Disease (ESRD) patients, which will result in improved cardiovascular outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Native Kidney Denervation in Patients With End Stage Renal Disease

NCT00551304

End Stage Renal Disease

COMPLETED PHASE1

Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial

NCT01392196

Heart Failure

TERMINATED NA

Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension

NCT00753116

Kidney Failure, Chronic Renal Dialysis

COMPLETED PHASE1

Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis

NCT06556407

Treatment Resistant Hypertension Chronic Hemodialysis

RECRUITING NA

REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.

NCT05703620

Chronic Kidney Diseases Heart Failure End Stage Renal Disease

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-stage Renal Disease Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renal Denervation

Renal denervation using a catheter-based Radio-frequency approach

Group Type EXPERIMENTAL

Renal Denervation

Intervention Type PROCEDURE

Renal Denervation

Usual Care

Usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renal Denervation

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Symplicity Renal Denervation Catheter

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* end stage renal disease
* hypertension (BP≥140/90mmHg)

Exclusion Criteria

* Individual has renal artery anatomy that is ineligible for treatment as assessed by the interventionalist.
* Individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No